1. Scrip
  2. >>New Products

AbbVie Ready To Leverage Migraine Franchise In Crowded Market

Qulipta Adds Indication Not Covered By Botox, Ubrelvy

 
• By Mandy Jackson

The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.

Woman suffers migraine while standing in a crowd of people
AbbVie brings seventh CGRP inhibitor to crowded migraine market • Source: Alamy

AbbVie Inc. has expanded its migraine franchise to three drugs with three different indications with the US Food and Drug Administration approval of its second CGRP inhibitor Qulipta (atogepant). It remains to be seen whether the triple-drug offering will provide a competitive advantage in the increasingly crowded anti-CGRP space, but the big pharma is expected to use its relatively long-term presence in the migraine market to its advantage.

AbbVie established itself as a player in the space through its $63bn acquisition of Allergan plc in 2019, gaining Botox (onabotulinumtoxinA) – approved for prevention of chronic migraine (15 or more headaches per month) in 2010 – and two oral CGRP inhibitors in late-stage development. (Also see "AbbVie Pounces On Chance To Buy Revenues In $63bn Mega-Deal For Allergan" - Scrip, 25 June, 2019.) Ubrelvy (ubrogepant) was approved at the end of 2019 as an acute treatment taken on-demand when patients experience migraine attacks

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

More from Scrip

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.